127 related articles for article (PubMed ID: 8650435)
1. Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities.
Malacarne P; Maestri A
Recenti Prog Med; 1996 Mar; 87(3):135. PubMed ID: 8650435
[No Abstract] [Full Text] [Related]
2. Warfarin, etoposide, and vindesine interactions.
Ward K; Bitran JD
Cancer Treat Rep; 1984 May; 68(5):817-8. PubMed ID: 6539172
[No Abstract] [Full Text] [Related]
3. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin.
Aki Z; Kotiloğlu G; Ozyilkan O
Am J Gastroenterol; 2000 Apr; 95(4):1093-4. PubMed ID: 10763974
[No Abstract] [Full Text] [Related]
4. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
5. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
7. [Medical treatment of early breast cancer: chemotherapy].
Ejlertsen B; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
[TBL] [Abstract][Full Text] [Related]
8. Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments.
Silva LM; Takahashi CS; Carrara HH
Teratog Carcinog Mutagen; 2002; 22(4):257-69. PubMed ID: 12111710
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the effects on the composition of alveolar surfactant of 2 chemotherapeutic protocols for carcinoma of the lung: peptichemio and MACC].
Balbi B; Benatti U; Morelli A; Sacco O; Vassallo F; Rossi GA; Ravazzoni C
Ann Ital Med Int; 1987; 2(1):22-30. PubMed ID: 3275275
[No Abstract] [Full Text] [Related]
10. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
11. A case of breast carcinoma late metastasis to the kidney.
Karamouzis MV; Liodantonaki P; Rigatos G
Am J Clin Oncol; 2006 Apr; 29(2):209-10. PubMed ID: 16601445
[No Abstract] [Full Text] [Related]
12. Unresolved issues in combination chemotherapy.
Wittes RE; Goldin A
Cancer Treat Rep; 1986 Jan; 70(1):105-25. PubMed ID: 3510730
[No Abstract] [Full Text] [Related]
13. Ascites in a woman with chronic mitral stenosis.
Litam PP; Smaha LA
Hosp Pract (Off Ed); 1991 May; 26(5A):35-6, 38. PubMed ID: 2033099
[No Abstract] [Full Text] [Related]
14. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil.
Brown MC
Pharmacotherapy; 1997; 17(3):631-3. PubMed ID: 9165571
[TBL] [Abstract][Full Text] [Related]
15. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Purdy MH
Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528
[TBL] [Abstract][Full Text] [Related]
16. Possible interactions between warfarin and antineoplastic drugs.
Seifter EJ; Brooks BJ; Urba WJ
Cancer Treat Rep; 1985 Feb; 69(2):244-5. PubMed ID: 3971397
[No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
18. [The effect of antitumor chemotherapy on the lipid spectrum of the erythrocyte membranes in lung cancer patients].
Novitskiĭ VV; Stepovaia EA; Bazhenova NG; Gol'dberg VE; Kolosova MV; Saprykina EV; Sokolova IB; Koreshkova KG; Bulavina IaV
Eksp Klin Farmakol; 1999; 62(1):56-9. PubMed ID: 10198770
[TBL] [Abstract][Full Text] [Related]
19. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.
Bonadonna G; Valagussa P; Veronesi U
J Clin Oncol; 2008 Jan; 26(3):342-4. PubMed ID: 18202404
[No Abstract] [Full Text] [Related]
20. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
